argenex (NASDAQ:ARGX) Sets New 52-Week High – Here’s What Happened

by · The Cerbat Gem

argenex SE (NASDAQ:ARGX – Get Free Report)’s stock price reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $855.70 and last traded at $848.70, with a volume of 92220 shares changing hands. The stock had previously closed at $832.35.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on ARGX. Zacks Research downgraded argenex from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 21st. Morgan Stanley lifted their target price on argenex from $766.00 to $1,040.00 and gave the company an “overweight” rating in a research report on Wednesday, October 1st. Royal Bank Of Canada lifted their target price on argenex from $850.00 to $860.00 and gave the company an “outperform” rating in a research report on Friday, October 31st. Stifel Nicolaus set a $882.00 target price on argenex in a research report on Thursday, September 18th. Finally, Truist Financial lifted their target price on argenex from $700.00 to $918.00 and gave the company a “buy” rating in a research report on Monday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $864.68.

Read Our Latest Report on argenex

argenex Price Performance

The firm has a market capitalization of $52.39 billion, a price-to-earnings ratio of 36.52, a P/E/G ratio of 0.88 and a beta of 0.45. The stock has a fifty day moving average of $777.07 and a two-hundred day moving average of $659.34.

Institutional Trading of argenex

A number of institutional investors and hedge funds have recently bought and sold shares of ARGX. GAMMA Investing LLC raised its stake in shares of argenex by 6.8% during the third quarter. GAMMA Investing LLC now owns 251 shares of the company’s stock valued at $185,000 after acquiring an additional 16 shares during the last quarter. Portside Wealth Group LLC raised its stake in shares of argenex by 2.8% during the third quarter. Portside Wealth Group LLC now owns 583 shares of the company’s stock valued at $430,000 after acquiring an additional 16 shares during the last quarter. Cromwell Holdings LLC raised its stake in shares of argenex by 10.0% during the third quarter. Cromwell Holdings LLC now owns 187 shares of the company’s stock valued at $138,000 after acquiring an additional 17 shares during the last quarter. Greenleaf Trust raised its stake in shares of argenex by 3.5% during the first quarter. Greenleaf Trust now owns 624 shares of the company’s stock valued at $369,000 after acquiring an additional 21 shares during the last quarter. Finally, Main Management ETF Advisors LLC raised its stake in shares of argenex by 1.7% during the second quarter. Main Management ETF Advisors LLC now owns 1,466 shares of the company’s stock valued at $808,000 after acquiring an additional 24 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenex Company Profile

(Get Free Report)

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

Read More